Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05960097 · ClinicalTrials.gov registry record · Phase 2
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 692
- Enrollment target
NCT05960097 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 692 participants.
The verdict
NCT05960097, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 692 participants
- Enrollment target
Study Summary
The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will compare the investigational vaccines to control vaccine. The purpose of Part B of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will compare the investigational vaccine under three different storage conditions.
Interventions
- BIOLOGICAL CV0701 mRNA COVID-19 Vaccine (Low dose)
- BIOLOGICAL CV0701 mRNA COVID-19 Vaccine (Medium dose)
- BIOLOGICAL CV0701 mRNA COVID-19 Vaccine (High dose)
- BIOLOGICAL CV0601 mRNA COVID-19 Vaccine
- BIOLOGICAL Control vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 692 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2024-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05960097
The ClinicalTrials.gov registry entry for NCT05960097 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 692 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which CV0701 mRNA COVID-19 Vaccine (Low dose) is the first listed.
NCT05960097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05960097 about?
NCT05960097 is a clinical study titled "A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults". The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will compare the investigational vaccines to control vaccine. The purpose of Part B of this study is to assess the immune response...
What is the current status of trial NCT05960097?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 692 participants. The study started on 2023-08-01. Estimated completion is 2024-08-30.
What interventions are being tested in trial NCT05960097?
The interventions under investigation include: CV0701 mRNA COVID-19 Vaccine (Low dose) (BIOLOGICAL), CV0701 mRNA COVID-19 Vaccine (Medium dose) (BIOLOGICAL), CV0701 mRNA COVID-19 Vaccine (High dose) (BIOLOGICAL), CV0601 mRNA COVID-19 Vaccine (BIOLOGICAL), Control vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05960097?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.